ITRM
Iterum Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ITRM
Iterum Therapeutics Plc
A clinical-stage pharmaceutical company focused on therapeutics for multi-drug rsistant pathogens
3 Dublin Landings, North Wall Quay, Dublin 1, Ireland
--
Iterum Therapeutics Plc was incorporated in Ireland on June 24, 2015. The company is a clinical-stage pharmaceutical company dedicated to the development and commercialization of sulopenem, which may be the first available oral penem in the United States and the first and only available oral and intravenous (IV) brand penem in the world. Sulopenem is a powerful, intravenously delivered antibiotic of thiopenem that is active against bacteria belonging to a group known as gram negative, causing urinary tract and intra-abdominal infections.
Earnings Call
Q3/2025
Estimate EPS-0.09
Actual EPS-0.16
Estimate Revenue--
Actual Revenue390.00K
Iterum Therapeutics' Q3 2025 Earnings Call: Contradictions Emerge on Sales Territory Coverage, Marketing Strategies, and Payer Coverage Expectations
Nov 14,2025 11:24
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS--
Actual EPS-0.13
Estimate Revenue--
Actual Revenue0
Iterum's Q2 2025: Unveiling Contradictions in Commercialization Strategy, Financial Health, and R&D Focus
Aug 13,2025 06:14
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ITRM has released its 2025 Q3 earnings. EPS was reported at -0.16, versus the expected -0.09, missing expectations. The chart below visualizes how ITRM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ITRM has released its 2025 Q3 earnings report, with revenue of 390.00K, reflecting a YoY change of NaN%, and net profit of -8.98M, showing a YoY change of -47.34%. The Sankey diagram below clearly presents ITRM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
